Biogen Announces New Hemophilia Spinoff Name

Source: Boston Globe

Aug 09, 2016

The hemophilia drug business that Biogen Inc. plans to spin off as a separate company early next year will be named Bioverativ.

Bioverativ will market Biogen’s two hemophilia drugs, Eloctate and Alprolix -- both approved in 2014 by the FDA -- and develop additional treatments for blood disorders.

The new company, based in the Boston area, will trade on the Nasdaq under the symbol BIVV.

Read the Boston Globe coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments